Logo image of HLVX

HILLEVAX INC (HLVX) Stock Fundamental Analysis

NASDAQ:HLVX - Nasdaq - US43157M1027 - Common Stock - Currency: USD

1.87  -0.05 (-2.6%)

Fundamental Rating

2

Taking everything into account, HLVX scores 2 out of 10 in our fundamental rating. HLVX was compared to 563 industry peers in the Biotechnology industry. While HLVX has a great health rating, there are worries on its profitability. HLVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HLVX has reported negative net income.
In the past year HLVX has reported a negative cash flow from operations.
HLVX had negative earnings in each of the past 5 years.
HLVX had a negative operating cash flow in each of the past 5 years.
HLVX Yearly Net Income VS EBIT VS OCF VS FCFHLVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

HLVX has a worse Return On Assets (-76.43%) than 67.85% of its industry peers.
HLVX has a Return On Equity (-95.33%) which is in line with its industry peers.
Industry RankSector Rank
ROA -76.43%
ROE -95.33%
ROIC N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HLVX Yearly ROA, ROE, ROICHLVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HLVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLVX Yearly Profit, Operating, Gross MarginsHLVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for HLVX has been increased compared to 1 year ago.
The number of shares outstanding for HLVX has been increased compared to 5 years ago.
There is no outstanding debt for HLVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HLVX Yearly Shares OutstandingHLVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
HLVX Yearly Total Debt VS Total AssetsHLVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.20, we must say that HLVX is in the distress zone and has some risk of bankruptcy.
HLVX has a Altman-Z score (-3.20) which is comparable to the rest of the industry.
There is no outstanding debt for HLVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.2
ROIC/WACCN/A
WACCN/A
HLVX Yearly LT Debt VS Equity VS FCFHLVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 10.84 indicates that HLVX has no problem at all paying its short term obligations.
HLVX has a Current ratio of 10.84. This is amongst the best in the industry. HLVX outperforms 82.24% of its industry peers.
HLVX has a Quick Ratio of 10.84. This indicates that HLVX is financially healthy and has no problem in meeting its short term obligations.
HLVX's Quick ratio of 10.84 is amongst the best of the industry. HLVX outperforms 82.42% of its industry peers.
Industry RankSector Rank
Current Ratio 10.84
Quick Ratio 10.84
HLVX Yearly Current Assets VS Current LiabilitesHLVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

HLVX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.32%.
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HLVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.16% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.76%
EPS Next 2Y24.41%
EPS Next 3Y15.04%
EPS Next 5Y10.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HLVX Yearly Revenue VS EstimatesHLVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M
HLVX Yearly EPS VS EstimatesHLVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HLVX. In the last year negative earnings were reported.
Also next year HLVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLVX Price Earnings VS Forward Price EarningsHLVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLVX Per share dataHLVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

HLVX's earnings are expected to grow with 15.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.41%
EPS Next 3Y15.04%

More info and screens

0

5. Dividend

5.1 Amount

HLVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HILLEVAX INC

NASDAQ:HLVX (5/6/2025, 3:18:50 PM)

1.87

-0.05 (-2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/amc
Earnings (Next)N/A N/A
Inst Owners54.36%
Inst Owner Change0.65%
Ins Owners2.24%
Ins Owner Change-0.15%
Market Cap93.76M
Analysts45.71
Price Target2.04 (9.09%)
Short Float %5.04%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.02%
Min EPS beat(2)-104.08%
Max EPS beat(2)-21.96%
EPS beat(4)0
Avg EPS beat(4)-35.91%
Min EPS beat(4)-104.08%
Max EPS beat(4)-4.06%
EPS beat(8)4
Avg EPS beat(8)-10.52%
EPS beat(12)6
Avg EPS beat(12)-24.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.28%
PT rev (3m)-33.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)25.82%
EPS NY rev (3m)28.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.61
EV/EBITDA N/A
EPS(TTM)-3
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.17
OCFYN/A
SpS0
BVpS3.08
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.43%
ROE -95.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.23%
ROA(5y)-132.64%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.84
Quick Ratio 10.84
Altman-Z -3.2
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
EPS Next Y53.76%
EPS Next 2Y24.41%
EPS Next 3Y15.04%
EPS Next 5Y10.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.36%
OCF growth 3YN/A
OCF growth 5YN/A